Jinling Hospital
Nanjing, Jiangsu, 210002, China
NCT Number: NCT07552532
This multicenter retrospective study is designed to develop and validate a CT-based multimodal risk stratification approach for postoperative local recurrence after curative-intent resection of non-small cell lung cancer (NSCLC). The approach integrates clinicopathologic variables, intratumoral and peritumoral radiomics, tumor-based 2.5D deep learning features, whole-lung deep learning features, and operative text features to capture complementary information related to tumor phenotype, pulmonary background, and surgical findings. Predictive performance and clinical utility will be evaluated in internal and external validation cohorts using the concordance index, time-dependent area under the receiver operating characteristic curve, decision curve analysis, and risk reclassification analyses. The objective of this study is to assess whether multimodal CT-based risk stratification may improve postoperative risk assessment and support individualized surveillance and management strategies.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Nanjing, Jiangsu, 210002, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From the date of surgery to first documented local recurrence, up to 3 years
Guangming Lu
Other
Multimodal CT-Based Risk Stratification of Postoperative Local Recurrence in Non-Small Cell Lung Cancer: A Multicenter Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05520099
Adenocarcinoma, Bladder Cancer
Little Rock, Arkansas, United States
View Trial DetailsNCT07537556
Bronchial Neoplasms, Carcinoma, Bronchogenic
Madrid, Spain
View Trial DetailsNCT07256002
Bronchial Neoplasms, Carcinoma, Bronchogenic
Beijing, Beijing Municipality, China
View Trial DetailsNCT07239544
Bronchial Neoplasms, Carcinoma, Bronchogenic
Suzhou, Jiangsu, China
View Trial Details